HGEN - Enrollment completed in Humanigen's early-stage ifabotuzumab study in glioblastoma multiforme

Humanigen (HGEN) has completed enrollment in its Phase 1 bioimaging study of ifabotuzumab in patients with recurrent glioblastoma multiforme ((GBM)).Results from the study, being conducted in Australia, are expected in H1 2021. The primary goal of the Phase 1 study is to evaluate safety of ifabotuzumab and to recommend a dose for a potential Phase 2 study either with ifabotuzumab or an antibody drug conjugate based on ifabotuzumab.Shares up 5% premarket.

For further details see:

Enrollment completed in Humanigen's early-stage ifabotuzumab study in glioblastoma multiforme